Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 WuXi PharmaTech Site Passes Inspection | Contract Pharma

What are you searching for?

Sign in
Breaking News

WuXi PharmaTech Site Passes Inspection

SynTheAll facility gets no 483s

By: Gil Roth

President, Pharma & Biopharma Outsourcing Association

WuXi PharmaTech has completed a general GMP and Pre-Approval Inspection (PAI) from the FDA for the manufacturing facility of WuXi’s wholly owned subsidiary Shanghai SynTheAll Pharmaceutical Co. Ltd. (STA). No Form 483 was issued.

STA has a manufacturing pipeline of small molecule APIs and advanced intermediates for global clients through its integrated platform, which extends from process research and research manufacturing to commercial manufacturing. The inspection outcome confirms STA’s capabilities.  

“The result of this inspection speaks to WuXi’s high standards of quality,” said Dr. Ge Li, chairman and chief executive officer of WuXi PharmaTech. “We continue to leverage our knowledge and that of our partners to build and operate a first-class quality system in China that meets global regulatory requirements.”

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics